**Supplemental Table 1**: *Comparisons between vaccine type*

|  |  |  |
| --- | --- | --- |
|  | **Mean** | **95% CI** |
| Unvaccinated | 22.9 | 22.8-23.0 |
| Janssen | 21.9 | 21.6-22.2 |
| Moderna | 22.5 | 22.3-22.7 |
| Pfizer | 22.0 | 21.8-22.1 |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **p-** | **p-** | **p-** | **p-** | **p-** | **p-** | **p-** |
| **value±** | **value1** | **value2** | **value3** | **value4** | **value5** | **value6** |
| <0.0001 | <0.0001 | 0.0052 | <0.0001 | 0.0064 | 0.9870 | 0.0001 |

‡ comparisons between all groups

**1**: comparison Unvaccinated vs. Janssen (adjusted for multiple comparisons using Tukey’s HSD method) **2**: comparison Unvaccinated vs. Moderna (adjusted for multiple comparisons using Tukey’s HSD method) **3**: comparison Unvaccinated vs. Pfizer (adjusted for multiple comparisons using Tukey’s HSD method)

**4**: comparison Janssen vs. Moderna (adjusted for multiple comparisons using Tukey’s HSD method)

**5**: comparison Janssen vs. Pfizer (adjusted for multiple comparisons using Tukey’s HSD method)

**6**: comparison Moderna vs. Pfizer (adjusted for multiple comparisons using Tukey’s HSD method)

**Supplemental Table 2**: *Comparison of Ct values in vaccinated and unvaccinated persons, stratified by age group (there is a significant interaction between age group and vaccination status, p<0.0001)*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **Not Vaccinated****Mean 95% CI** | **Vacci****Mean** | **nated****95% CI** | **Effect size *d*** | **p-value** |
| 0-11 yr | 23.9 | 23.7-24.1 | 19.8 | 16.5-23.8 | 0.79 | 0.0466 |
| 12-18 yr | 23.0 | 22.8-23.3 | 23.9 | 22.5-23.5 | 0.00 | 0.9242 |
| 19-35 yr | 22.4 | 22.2-22.6 | 23.0 | 22.1-22.6 | 0.00 | 0.8846 |
| 36-60 yr | 22.3 | 22.1-22.5 | 21.9 | 21.8-22.1 | 0.07 | 0.0080 |
| >61 yr | 22.3 | 21.9-22.8 | 22.1 | 21.8-22.3 | 0.05 | 0.3239 |

**Supplemental Table 3**: *Comparison of Ct values in vaccinated and unvaccinated persons, stratified by sex.*

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Unvaccinated****Mean 95% CI** | **Vaccinated****Mean 95% CI** | **Effect size *d*** | **p-value** |
| Female | 23.0 22.9-23.2 | 22.3 22.1-22.4 | 0.14 | <0.0001 |
| Male | 22.8 22.6-22.9 | 22.0 21.8-22.1 | 0.15 | <0.0001 |

**Supplemental Figure 1. Concordance between self-reported vaccination status and records in public health vaccine registries.** Individuals were considered fully vaccinated based on vaccine registry (WIR/WEDSS) data if the registries indicated receipt of a final vaccine dose at least 14 days prior to submitting the sample used in our analysis. For individuals whose vaccination status could not be verified in the registry, self-reported data collected at the time of testing were used. Individuals were considered unvaccinated based on self-report only if there was an explicit declaration of unvaccinated status in the self-reported data. Individuals were considered fully vaccinated based on self-report if they fulfilled all of the following criteria: (1) indicated that they had received a COVID vaccine prior to testing; (2) indicated that they did not require another vaccine dose; and (3) reported a date of last vaccine dose that was at least 14 days prior to testing.

Specimens lacking data on vaccination status were excluded from the study. Specimens from partially vaccinat- ed individuals (incomplete vaccine series, or <14 days post-final dose) were also excluded. Specimens from indi- viduals who received a booster prior to sample collection were also excluded as non-equivalent to those fulfilling the criteria to be considered fully vaccinated. **A.** Of 20,431 specimens with vaccination status available from at least one source, 5,078 specimens had data available from both sources. Under-reporting of full vaccination status in self-reports 1,064/6,142 or 17%) was more common than over-reporting (409/5,487 or 7.4%). **B.** N1 Ct values for SARS-CoV-2-positive specimens grouped by vaccination status for individuals whose vaccination status was determined by vaccine registry or by self-reported data.

**Supplemental Figure 2. Log transformation of raw Ct values results in normally distributed residuals.** Raw Ct values were not normally distributed, so we log-transformed all Ct values prior to ANOVA, and confirmed normality by plotting residuals and normal probability.

**Supplemental Figure 3. Density distributions of unvaccinated and vaccinated specimen collection dates by day since symptom onset.** Day 0 on the x-axis denotes self-reported day of symptom onset. Negative values for days indicate specimen collection prior to symptom onset. Symptom onset data were available for n=6,871 unvaccinated cases and n=5,522 vaccinated cases. Two-sided K-S test: p=0.0012; median days since symptom onset were 2.4 for both unvaccinated and vaccinated cases.

**Supplemental Figure 4. Infectious SARS-CoV-2 detected in the majority of fully vaccinated individuals with low Ct values.** Infectiousness was determined for a subset of N1 Ct-matched specimens with Ct <25 by in- oculation onto Vero E6 TMPRSS2 cells, then determining presence or absence of cytopathic effects (CPE) after 5 days in culture. Specimens with unknown vaccination status were excluded from the analysis. Circles indicate presence of CPE; ‘X’ indicates no CPE detected.

**Supplemental Figure 5. Ct values do not differ substantially by vaccine type. A.** Comparison of mean N1 Ct values in all specimens, stratified by vaccine type shows negligible effect (*d* < 0.2) of vaccine type on Ct val- ue at time of positive test, relative to unvaccinated persons. **B.** The time analysis showed a decrease in N1 Ct values with time over 7 months. Combining all three vaccines, there was a significant decrease over the first 7 months, with a slope of -0.18 (95% CI: -0.26 - 0.10), p value <0.0001. Individually, Janssen had a slope -0.19 (95% CI: -0.38 to -0.001, p-value=0.060), Moderna had a slope of -0.13 (95% CI: -0.28 - 0.02, p-value=0.092),

Pfizer had a slope of -0.24 (95% CI: -0.24 to -0.13, p-value<0.0001).